Skip to content

Alvotech

US · ALVO #2709 by market cap Listed 2020
4.12 -0.17 -3.96%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio -5.59 In line with history 53rd percentile
5-year average -6.34
P/E ratio -5.11 In line with history 50th percentile
5-year average 1.00 · forward 19.86
P/S ratio 3.04 Cheap vs history 27th percentile
5-year average 18.53 · forward 1.68 · #47 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Alvotech (ALVO) 1.47B -5.02 -5.50 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value6.43 Economic moatNone UncertaintyVery High

Trading 56.1% below Morningstar's fair value estimate.

Fair value

While Alvotech may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 35% discount to our quantitative fair value estimate of $6.43 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's long term debt to assets ratio falls in the top 1% globally. The firm has a high level of long-term debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be cheap.

On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 40% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Alvotech discussion 0 comments

Add a comment